Tilray Just Posted Record Quarterly Revenue of $257 Million. So Why Did Its Cannabis Sales Shrink?

Tilray reported record fiscal Q1 2027 revenue of $257.1 million, up 23% year over year, and gross profit of $77.5 million, up 35%, as beverage revenue rose 82% to $101.5 million. Cannabis revenue fell 13% to $56.1 million, while Tilray recorded an approximately $40 million net loss, adjusted EBITDA declined to $9.2 million from $10.2 million, and free cash flow was negative $27.4 million. Management reaffirmed fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million; the results show strong revenue growth but persistent profitability and cannabis-market challenges.

Analysis

The key underwriting issue is revenue quality, not the headline growth rate. Beverage expansion appears substantially acquisition-led, while the legacy cannabis engine is shrinking; meanwhile, higher gross profit has not translated into higher adjusted EBITDA. That points to weak incremental operating leverage, although the release does not provide enough detail to attribute the gap among integration costs, overhead, or other items. Do not capitalize the revenue mix shift as a durable margin upgrade until organic beverage growth and cash conversion are visible.

For the next 1–3 months, the main catalyst is whether management can meet its EBITDA range without worsening cash burn. Track segment organic growth, working-capital movements, and quarterly free cash flow. One negative-FCF quarter is not enough to infer a financing need, but persistent burn would make the reported liquidity cushion less reassuring and could constrain strategic flexibility. Over 6–18 months, international cannabis growth may help, but it does not yet offset Canadian weakness; peers exposed to Canadian adult-use demand face a similar pricing and volume risk, while beverage competitors could benefit if Tilray prioritizes distribution or investment outside cannabis.

Contrarian angle: the diversification may reduce dependence on cannabis, but it also weakens the simple “global cannabis legalization” equity narrative. The market could be over-crediting acquired sales and underweighting execution; conversely, sustained beverage growth plus positive FCF could justify treating Tilray more as a consumer-products platform. No valuation or price data here supports a directional entry. Falsifiers: consecutive quarters of positive FCF and EBITDA growth would weaken the cautious view; guidance reduction, further cannabis contraction, or liquidity deterioration would strengthen it.

Key Decisions for Investors

• Avoid chasing the revenue beat; wait for the next report to separate organic beverage growth from acquisition contribution and assess whether EBITDA converts to cash.
• Keep TLRY on a catalyst watch rather than initiating a valuation-based position without current price and balance-sheet detail. Reassess if quarterly free cash flow turns sustainably positive or management cuts its EBITDA outlook.
• For any existing long exposure, use quarterly FCF, adjusted EBITDA versus guidance, and Canadian cannabis revenue as explicit trim/add triggers; do not treat international growth alone as evidence that the core business has stabilized.
• Monitor Canadian cannabis peers for correlated demand or pricing deterioration, but avoid a sector short based solely on Tilray’s results; company-specific mix and acquisition effects limit read-through.